$0.64
1.34% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US28623U1016
Symbol
ELEV
Sector
Industry

Elevation Oncology Inc Stock price

$0.64
-0.20 23.27% 1M
-1.49 69.76% 6M
+0.08 14.49% YTD
-2.33 78.31% 1Y
-3.23 83.38% 3Y
-10.80 94.37% 5Y
-10.80 94.37% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.00 0.62%
ISIN
US28623U1016
Symbol
ELEV
Sector
Industry

Key metrics

Market capitalization $38.08m
Enterprise Value $-33.97m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 0.55
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.01m
Cash position $103.07m
EPS (TTM) EPS $-0.81
P/E forward negative
Short interest 15.98%
Show more

Is Elevation Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Elevation Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Elevation Oncology Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Elevation Oncology Inc forecast:

Buy
100%

Financial data from Elevation Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.03 0.03
25% 25%
-
-0.03 -0.03
25% 25%
-
- Selling and Administrative Expenses 15 15
2% 2%
-
- Research and Development Expense 27 27
24% 24%
-
-42 -42
18% 18%
-
- Depreciation and Amortization 0.03 0.03
25% 25%
-
EBIT (Operating Income) EBIT -42 -42
18% 18%
-
Net Profit -42 -42
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Elevation Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elevation Oncology Inc Stock News

Neutral
PRNewsWire
23 days ago
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer --  -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoin...
Neutral
PRNewsWire
about 2 months ago
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload -- – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and ...
Neutral
PRNewsWire
about 2 months ago
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologies AMSTERDAM , Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its ...
More Elevation Oncology Inc News

Company Profile

Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.

Head office United States
CEO Joseph Ferra
Employees 29
Founded 2019
Website www.elevationoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today